Trials / Completed
CompletedNCT06196905
An Exploratory Study of MT-2990 in Patients With AAV
An Exploratory Study of MT-2990 in Patients With Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To explore the efficacy, safety, pharmacokinetics and mechanism of action of MT-2990 in patients with AAV.
Detailed description
Target sample size is 5\~10 subjects administered MT-2990
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-2990 | i.v. infusion |
Timeline
- Start date
- 2024-06-24
- Primary completion
- 2026-01-14
- Completion
- 2026-01-14
- First posted
- 2024-01-09
- Last updated
- 2026-02-04
Locations
8 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06196905. Inclusion in this directory is not an endorsement.